👀 Ones to watch: The MOST undervalued stocks to buy right nowSee Undervalued Stocks

AstraZeneca shares dip after lung cancer drug trial update 'disappoints' hopes

Published 07/03/2023, 07:50 PM
© Reuters.
AZN
-

Investing.com -- AstraZeneca (LON:AZN) has announced that its experimental precision drug has shown improvement in slowing the progression of lung cancer in a late-stage trial, however, shares slipped on Monday after analysts noted that the findings disappointed expectations.

In a statement, the British pharmaceutical firm said the drug, datopotamab deruxtecan, demonstrated "statistically significant" improvement in progression-free survival when compared to standard chemotherapy treatments in patients with locally advanced or metastatic non-small cell lung cancer with at least one prior round of therapy.

“We are encouraged by the statistically significant results of the dual primary endpoint of progression-free survival seen with datopotamab deruxtecan and look forward to the final overall survival analysis. We plan to share these data with regulatory authorities to discuss next steps,” said Ken Takeshita, global head of oncology research and development at Japan's Daiichi Sankyo, which is jointly developing the drug with AstraZeneca.

The treatment is an example of so-called antibody drug conjugates (ADC), a class of drug that combines a monoclonal antibody with a chemotherapy-laden payload. It has been described as a "guided missile" which aims to attack cancer cells while sparing healthy cells.

AstraZeneca said the trial of the drug will continue "as planned."

But analysts at Bank of America Securities flagged that the latest update from the company did not include the wording "clinically meaningful," which had been an important gauge of the trial's success.

"Data was statistically significant, however, headline did not specify a clinically relevant improvement in [progression-free survival], where AZN had noted it would use clinically meaningful to describe PFS if benefit [was greater than] 2-3 months," the analysts said.

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.